Skip to content

COVID-19 Vaccination

Injection

The much-awaited second phase of India’s COVID-19 vaccination
drive began on April 1 and will cover people above 60 years of
age and those above 45 with co-morbidities. Slot booking
started at 9 AM on Monday (March 1).

Third Phase will begin on April 1 and will cover people above 45 years of age.

Getting vaccinated and following safety protocols are the besttools to protect yourself and your loved ones from COVID-19. Let’s take a step towards ending this pandemic and its growing negative impact on healthcare, education, economy and countless other activities of our lives.

How to register for the Covid vaccine?

  • Log on to www.cowin.gov.in or by Aarogya Setu App on mobile
  • Enter your mobile number and get an OTP to create your account
  • Once your number is verified, you will be directed to the ‘registration of the vaccination’ page
  • Fill in your name, age, gender, comorbidities, upload an identity document and click on the ‘register’ button
  • Once registered, a citizen can further add 3 more people under the ‘account details’ section
  • Then click on the ‘schedule appointment’ button
  • Select a vaccination centre of choice by state, district, block and pin code using the dropdown
  • Check time & availability, and book your slot
  • On successful completion of booking, you will receive a message. Show this message at the vaccination centre
  • After you have taken the first dose, the booking of the second dose will be done automatically.

Find the list of all the vaccination centers in India here:

Vaccination Centers

Which documents will you need to get vaccinated?

To become a beneficiary of the COVID Vaccination programme
being run by the government, you will need one of the following
to register –

  • Aadhar card
  • Voter ID card
  • Driving license
  • PAN card
  • MGNREGA employment card
  • Service identity card
  • Passport
  • Smart card
  • Pension identity
  • Office identity card
  • Bank/ Post office passbook
  • Health insurance card

The beneficiary must also carry one of these documents when
he/she shows up at the COVID vaccination Centre.
Register on the Co-WIN website and when your turn arrives,
get vaccinated. It can save your life. But remember to observe
the COVID protocol such as social distancing, hand sanitizing,
and wearing masks before and even after vaccination.

Contraindication of Getting Vaccine

Persons with history of:

Anaphylactic or allergic reaction to a previous dose of COVID-19 vaccine

Immediate or delayed-onset anaphylaxis or allergic reaction to vaccines or injectable therapies, pharmaceutical products, food-items etc.

Pregnancy & Lactation:

Pregnant & Lactating women have not been part of any COVID-19 vaccine clinical trial so far. Therefore, women who are pregnant or not sure of their pregnancy; and lactating women should not receive COVID-19 vaccine at this time

Provisional / temporary contraindications:

In these conditions, COVID-19 vaccination is to be deferred for 4-8 weeks after recovery

Persons having active symptoms of SARS-CoV-2 infection.

SARS-COV-2 patients who have been given anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma

Acutely unwell and hospitalized (with or without intensive care) patients due to any illness.

Types of Vaccines for COVID-19

Most Vaccination Centers are giving COVISHIELD vaccine manufactured by Serum Institute Pune and Developed by Astra Zaneca and Oxford University

Few are also getting COVAXIN vaccine manufactured by Bharat Serum

Covishield

COVISHIELD

https://www.seruminstitute.com/product_covishield.php

ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant)

COVISHIELD vaccine is manufactured by Serum Institute Pune and Developed by Astra Zaneca and Oxford University.

 IN PREVENTION OF (COVID-19) DISEASE IN INDIVIDUALS 18 YEARS OF AGE AND OLDER

Ingredients of COVISHIELD Vaccine

The COVISHIELD™ Vaccine includes the following ingredients: L-Histidine, L-Histidine hydrochloride monohydrate, Magnesium chloride hexahydrate, Polysorbate 80, Ethanol, Sucrose, Sodium chloride, Disodium edetate dihydrate (EDTA), Water for injection.

Fact Sheet for COVISHIELD

Covaxin

COVAXIN

COVAXIN®, India’s indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).

The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) high containment facility.

The vaccine is developed using Whole-Virion Inactivated Vero Cell derived platform technology. Inactivated vaccines do not replicate and are therefore unlikely to revert and cause pathological effects. They contain dead virus, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection.

Why develop Inactivated Vaccine? 

Conventionally, inactivated vaccines have been around for decades. Numerous vaccines for diseases such as Seasonal Influenza, Polio, Pertussis, Rabies, and Japanese Encephalitis use the same technology to develop inactivated vaccines with a safe track record of >300 million doses of supplies to date. It is the well-established, and time-tested platform in the world of vaccine technology.

Key Attributes:

COVAXIN® is included along with immune-potentiators, also known as vaccine adjuvants, which are added to the vaccine to increase and boost its immunogenicity.

It is a 2-dose vaccination regimen given 28 days apart.

It is a vaccine with no sub-zero storage, no reconstitution requirement, and ready to use liquid presentation in multi-dose vials, stable at 2-8oC.

Pre-clinical studies: Demonstrated strong immunogenicity and protective efficacy in animal challenge studies conducted in hamsters & non-human primates.

The vaccine received DCGI approval for Phase I & II Human Clinical Trials in July, 2020.

A total of 375 subjects have been enrolled in the Phase 1 study and generated excellent safety data without any reactogenicity. Vaccine-induced neutralizing antibody titers were observed with two divergent SARS-CoV-2 strains. Percentage of all the side-effects combined was only 15% in vaccine recipients. For further information, visit our blog page on phase 1 study.